St. Jude Care & Treatment

Menu

Close

Recruiting

HAP3HCT: Transplant with Memory T Cells for Blood Cancer

About this study

Many children and young adults with high-risk blood cancers need stem cell (bone marrow) transplants but do not have fully matched donors. A full match means the donor and patient have very similar immune markers, called HLA, which helps the body accept the new cells. The HAP3HCT clinical trial tests a new kind of transplant that uses stem cells from a partially matched family member.

In this kind of transplant, doctors remove certain immune cells from the donated cells before giving them to the patient. These removed cells (called naïve T cells) can cause a serious side effect called graft-versus-host disease (GVHD). By taking these T cells out, doctors hope to reduce that risk.

Before the donor cells are given, patients will receive a combination of chemotherapy and antibodies to prepare their body for the transplant. After the transplant, patients receive memory T cells from the same donor. These are special immune cells that "remember" how to fight infections. Because they have experience fighting germs, memory T cells may help the immune system recover faster and protect the patient without causing GVHD.

Some patients will also get a targeted therapy called blinatumomab after the transplant. This medicine is a type of immunotherapy that helps the patient’s immune system find and attack any remaining cancer cells.

The main goal of the study is to see if this approach is safe and if it helps the immune system recover well. 

Eligibility overview

  • Age 21 or younger
  • Diagnosed with a high-risk blood cancer
  • No fully matched stem cell donor available
  • Eligible for a partially matched (haploidentical) transplant
  • Must have a family member who can be the donor

Request a referral

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

TCRαβ-Depleted Progenitor Cell Graft with Additional Memory T-Cell DLI, Plus Selected Use of Blinatumomab, in Naïve T-Cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

Study goal:

To study whether using memory T cells and blinatumomab in a special type of haploidentical stem cell transplant is safe and supports immune recovery in patients with blood cancers.

Diagnosis:

Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Chronic Myeloid Leukemia

Age:

Birth to 21 years

Clinical trials categories:

Blood Disorders Chronic Myeloid Leukemia Acute Myeloid Leukemia (AML) Leukemia Myelodysplastic Syndromes Acute Lymphoblastic Leukemia (ALL)

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more